CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Over the past seven years, the landscape of mRCC treatment has dramatically shifted with the introduction of tyrosine kinase inhibitors (TKI) and immuno-oncology (IO) agents.
Metastatic renal cell carcinoma (mRCC) treatment has been experiencing a dramatic transformation in recent years, with the approval of new drugs and the advent of innovative therapeutic strategies. However, key knowledge gaps persist in patient management and therapy selection. In response to this, an ongoing observational study called ODYSSEY RCC, backed by multiple universities and pharmaceutical companies, seeks to address these gaps and establish more effective treatment protocols.
Key Points:
- ODYSSEY RCC, a prospective, observational cohort phase IV study, was launched in 2022 to assess changes in the therapeutic landscape of mRCC. The study will run until 2026 and involve 800 patients.
- The primary objective of ODYSSEY RCC is to identify distinct patterns of change in the quality of life and symptom burden in mRCC patients undergoing treatment in different settings.
- In addition to evaluating the efficacy of different combination regimens, the study will examine secondary outcomes, including treatment selection, dosing, duration of treatment, and overall survival.
- Data collection for patient-reported outcomes is scheduled to occur at baseline, every three months for two years, and then every six months until the end of follow-up.
Additional Points:
- In 2022, the American Society of Clinical Oncology (ASCO) published its first comprehensive clinical practice guidelines for the management of metastatic clear-cell RCC.
- These guidelines include answers to six key clinical questions, 20 recommendations, and highlight the importance of predictive and prognostic biomarkers in refining treatments.
- The guidelines also emphasize the need for ongoing patient-clinician communication and multidisciplinary team input for effective mRCC care.
- Apart from ASCO’s guidelines, various reviews have been discussing the evolving terrain of metastatic kidney cancer, focusing on non-clear cell metastatic RCC, not covered in ASCO’s 2022 guidelines.
Conclusion:
- The management of mRCC is undergoing significant evolution. Initiatives such as the ODYSSEY RCC study and ASCO guidelines are instrumental in navigating this shifting landscape, addressing knowledge gaps, and improving patient outcomes.
Nephrology Latest Posts
- Extraosseous Calcification in Kidney Disease
- Evaluating Troponin Elevation in Patients with Chronic Kidney Disease and Suspected Acute Coronary Syndrome
- Should I Start an SGLT-2 Inhibitor in my Patient with Heart Failure and Chronic Kidney Disease?
- Adjuvant Pembrolizumab after Nephrectomy in Renal Cell Carcinoma
- Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
Did You Know?
Renal cell carcinoma accounts for about 90% of all kidney cancers, making research such as the ODYSSEY RCC study crucial for improving patient outcomes.
